Friday, June 10, 2016 11:53:32 AM
Benzinga
By R. Chandrasekaran
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) disclosed positive top-line results from its Phase IIb study, which was meant to evaluate the safety and efficacy of its oral insulin capsule in patients with type 2 diabetes. According to the company, the trial's principal goal, a significant drop of weighted mean night-time glucose, was achieved successfully.
The company's CEO, Nadav Kidron, was pleased to say, "This demonstration of safe and effective oral insulin delivery represents a transformative event in the treatment of type 2 diabetes. We are delighted with the results and look forward to moving into Phase III trials."
Oramed said this double blind, 28 day, randomized trial of 180 adult type 2 diabetic patients demonstrated a statistically significant drop in the primary endpoint, pooled night-time glucose mean percentage change of 6.47 percent from run-in, between placebo and active cohorts. Additionally, the trial also demonstrated a good safety profile with no drug related serious adverse events.
Commenting on the developments, Head of Oramed's Scientific Advisory Board, Michael Berelowitz, said, "These are very impressive results that confirm the efficacy of orally delivered intestinally absorbed insulin. The promise of this more physiological delivery system for insulin is the inhibition of hepatic glucose production, which was clearly demonstrated via the significant reduction in night-time glucose levels in patients who received ORMD-0801."
The Company indicated it intends to present, as well as publish more comprehensive data in the future..
Recent ORMP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:06:24 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/16/2024 08:42:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:05:24 PM
- Oramed Letter to Shareholders • PR Newswire (US) • 06/26/2024 01:05:00 PM
- Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 06/20/2024 11:32:05 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/20/2024 11:30:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 09:28:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 09:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:00:27 PM
- Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation • GlobeNewswire Inc. • 03/19/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:42:26 PM
- Oramed Letter to Shareholders • PR Newswire (US) • 02/20/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:43:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:41:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:39:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:37:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:36:18 PM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM